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Abstract
VEGFA is an angiogenic factor secreted by tumors, in particular those with VEGFA amplifi-
cation, as well as by macrophages and lymphocytes in the tumor microenvironment. Here
we sought to define the presence of M1/M2 macrophages, PD-1-positive lymphocytes and
PD-L1 tumoral and stromal expression in colorectal cancers harboring VEGFA amplification
or chromosome 6 polysomy. 38 CRCs of which 13 harbored VEGFA amplification, 6 with
Chr6 polysomy and 19 with neutral VEGFA copy number were assessed by immunohis-
tochemistry for CD68 (marker for M1/M2 macrophages), CD163 (M2 macrophages), pro-
grammed death 1(PD-1)- tumor infiltrating and stromal lymphocytes as well as tumoral and
stromal PD-1 ligand (PD-L1) expression. CRCs with VEGFA amplification or Chr6 polysomy
were associated with decreased M1/M2 macrophages, reduced PD-1-expressing lympho-
cyte infiltration, as well as reduced stromal expression of PD-L1 at the tumor front. Com-
pared to intermediate-grade CRCs, high-grade CRCs were associated with increased M1/
M2 macrophages and increased tumoral expression of PD-L1. Our results suggest that
VEGFA amplification or Chr6 polysomy is associated with an altered tumor immune
microenvironment.
Introduction
The complex interactions between tumor cells and non-tumoral cells within the tumor micro-
environment contribute to the hallmarks of cancer cells [1]. The tumor microenvironment is
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composed of many different cell types including endothelial cells, pericytes, fibroblasts and
immune cells [1]. The recent promising results of PD-1/PD-L1 blockade as an immunotherapy
check-point in different cancer entities [2–5] have underscored the essential role of the
immune system in the control of tumor growth.
Tumor-associated macrophages (TAMs) are found within tumors as well as in the sur-
rounding non-malignant tissues [6] and can be either pro- or anti-tumorigenic in response to
environmental changes [7–9]. Macrophages are broadly classified into two major groups, M1
and M2. M1 macrophages are involved in inflammatory response, pathogen clearance and
antitumor immunity through the expression of pro-inflammatory cytokines such as IL-1β,
IL-6, IL-12, IL-23, TNFα and nitric oxide synthase 2 (iNOS) [6,10–13]. By contrast, M2 macro-
phages are known to promote tissue remodeling and repair, angiogenesis and tumor progression
[14,15]. M2 macrophages release anti-inflammatory cytokines such as IL-10 and transforming
growth factor β (TGFβ) and are characterized by an upregulation of mannose receptors (e.g.
CD206) and arginase-1, and a downregulation of iNOS production [10,16,17]. The prognostic
implication of the extent of macrophage infiltration is uncertain in colorectal carcinomas
(CRCs) with reports variably showing associations with favorable prognosis [18] and with
adverse prognosis [19] but is generally associated with poor prognosis in other cancer types
[20,21]. The contradictory results may be associated with the type and localization of macro-
phages in the tumor and/or with macrophage infiltration at the tumor front [18].
Activated T-cells and other immune cells typically show upregulation of programmed cell
death-1 (PD-1), which plays an immune-suppressive role when bound to its ligand PD-L1 [2].
PD-L1 is expressed by T and B cells, dendritic cells, macrophages, endothelial, muscle and
pancreatic cells [22] and its upregulation in cancer cells has been implicated in shutting down
immune response in cancer cells [22]. The interaction between PD-1 and PD-L1 results in the
downregulation of lymphocyte proliferation and cytokine production [23]. Tumor infiltrating
PD-1-positive T-cells and tumoral expression of PD-L1 have been associated with poor prog-
nosis in several tumors, including esophageal, pancreatic, gastric, hepatocellular, urothelial
and renal cell carcinomas, follicular lymphoma, melanoma as well as soft tissue sarcomas [23–
33]. However, the role of PD-1/PD-L1 in CRC is controversial [22,34]. The contradictory
results may be caused by technical limitations, as well as by the heterogeneity and variability of
these markers which are strongly affected by temporal and spatial factors [34], leading to dif-
ferent interpretation when detected in different sections of the same tumor.
Recently, we showed that a subgroup (~7%) of highly aggressive CRCs harbor copy number
amplification of vascular endothelial growth factor A (VEGFA), a member of the vascular
endothelial growth factor (VEGF) family, which also includes VEGFB, VEGFC, VEGFD and
placental growth factor (PlGF) [35]. VEGFs have been shown to play multi-faceted roles in
stimulating neo-angiogenesis and tumor growth [36] and among the VEGFs, VEGFA, in par-
ticular, has been shown to mediate angiogenesis, a critical step in both tumor growth and
metastasis formation [2,37]. In fact, VEGFA is a key regulator of proliferation, survival, migra-
tion and permeability of blood endothelial cells in both physiological and pathological angio-
genesis [2,37]. Consistent with these results, copy number amplification and overexpression of
VEGFA have been associated with poor prognosis in various cancer types [38–40]. In addition
to its well-documented angiogenic roles, VEGFA has also been shown to have immunosup-
pressive properties, including the inhibition of dendritic cell maturation and T-cell production
[41,42]. In fact, a recent study demonstrated that VEGFA produced in the tumor microenvi-
ronment directly increases PD-1 expression on intratumoral CD8+ T-cells and combined
anti-PD-1 and anti-VEGFA blockade showed a synergistic effect in tumors with high levels of
VEGFA [43]. It is also important to note that in addition to tumor cells, macrophages and, to a
lesser extent, tumor infiltrating lymphocytes (TIL), represent major sources of VEGFA, and
VEGFA amplification and the tumor microenvironment
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macrophage-produced VEGFA has been shown to promote tumor angiogenesis and invasion
[44,45]. Thus the interactions between tumors with VEGFA amplification, macrophages and
PD-1-expressing lymphocytes are likely to be intricate.
To address the question whether there is any association of VEGFA copy number status
and alterations of the immune microenvironment in CRCs, we performed an immunohisto-
chemical study to define the presence of M1/M2 macrophage (using CD68 and CD163 as
markers for M1/M2 and M2 macrophages, respectively), the presence of PD-1-positive tumor
infiltrating and stromal lymphocytes and the distribution of PD-L1 expression in the tumor
and the stroma. We found that VEGFA gene copy number amplification/polysomy was associ-
ated with reduced macrophages, PD-1-positive tumor infiltrating lymphocytes and PD-L1
stromal expression.
Materials and methods
Ethics
Samples were anonymized prior to analysis and the study has been approved by the Institu-
tional Review Board of the Institute of Pathology, University Hospital Basel (USB), Switzer-
land, and the Ethics Committee of Nordwest/Central Switzerland (EKNZ). Participants in the
USB underwent a written, informed consent process at enrolment.
Tissue samples
The biobank at the Institute of Pathology, University Hospital Basel, Switzerland, was searched
for CRCs diagnosed between 2007 and 2013. In total, formalin-fixed paraffin-embedded
(FFPE) samples of 150 CRCs and 45 adjacent non-malignant tissue samples were retrieved.
Additionally, whole sections of 8 CRCs previously found to harbor VEGFA copy number
amplification (n = 2) or chromosome 6 polysomy (n = 6) [35] were retrieved from the Insti-
tutes of Pathology of the Cantonal Hospitals of Aarau and St. Gallen, Switzerland.
Tissue microarray (TMA) construction
All FFPE samples had sufficient material for TMA construction. Hematoxylin and eosin-
stained sections were obtained from each FFPE block to define representative tumor tissue
regions. TMAs were constructed by punching the regions of interest using core cylinders of 1
mm diameter using TMA-GM1 (Sysmex AG, Switzerland). Four-μm-thick slides of the result-
ing TMAs were cut using Microtome (Thermo Fisher Scientific Inc., USA).
Fluorescence In Situ Hybridization (FISH)
FISH for VEGFA gene copy number status was performed using validated protocols estab-
lished at the Institute of Pathology at the University Hospital Basel as described previously
[35,46]. VEGFA-amplified cases were defined as a VEGFA/Chr6 ratio of<2.0 and an average
VEGFA copy number of6.0 signals per cell or a VEGFA/Chr6 ratio2.0 with an average
VEGFA copy number of4.0 signals per cell. Samples with a VEGFA/Chr6 ratio of<2.0 and
an average VEGFA copy number <4.0 signals per cell were classified as not amplified. Samples
with a VEGFA/Chr6 ratio <2.0 and an average VEGFA copy number 4.0 and<6.0 signals
per cell were classified as equivocal. For Chr6 polysomy status, low polysomy 6 was defined as
an average between 2.26 and 3.75 Chr6 copy number and high polysomy 6 was defined as an
average higher than 3.75 Chr6 copy number [46]. For TMA punches that were positive or
equivocal for VEGFA amplification or Chr6 polysomy, FISH was performed on a whole slide
VEGFA amplification and the tumor microenvironment
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from the corresponding FFPE block to confirm the positive results or to resolve the equivocal
cases [35,46].
Immunohistochemistry
Whole FFPE sections were pre-treated with CC1 (Ventana Medical Systems, Tucson, Arizona,
USA) as previously described [47] and incubated with primary antibodies against CD68
(IR613, Dako, Denmark, pre-diluted), CD163 (Cat. No. 760–4437, Ventana Medical Systems
Inc., USA, pre-diluted), PD-1 (Cat. No. 760–4895, Ventana Medical Systems Inc., USA) and
PD-L1 (Cat. No. 13684, Cell Signaling Technology, USA). Positive and negative controls were
included in each experiment. Immunohistochemistry for each marker was evaluated twice by
the same observer (KB) using the BX43 light microscope (Olympus, Japan). Discordant cases
were reviewed by two pathologists with a special interest in gastrointestinal pathology (LT and
LMT) to reach a consensus. Representative micrographs were acquired using the cellSens
Dimension software (Olympus, Japan) and the DP73 Camera (Olympus, Japan) installed on
the BX43 light microscope.
For CD68 (M1/M2 macrophage marker) and CD163 (M2 macrophage marker), IHC scor-
ing was performed for 4 randomly selected fields at the tumor front for each case. The number
of macrophages was counted for each marker on a total field of 2.2 mm2 using the ImageJ pro-
gram (version 1.46r). Semi-quantitative/ categorical comparisons were also performed using
the following thresholds. For CD68-positive macrophages, fewer than 100 macrophages was
considered low infiltration, between 100 and 130 moderate infiltration and more than 130
high infiltration. For CD163-positive macrophages, fewer than 60 macrophages was defined as
low infiltration, between 60 and 90 macrophages as moderate infiltration and more than 90
macrophages as high infiltration.
For PD-1, 4 random spots at the tumor front of each case were selected and photographed
with a 40X objective and a 10X ocular with a total magnification of 400X. A total of 152 pic-
tures in 38 tumors were evaluated. PD-1 expression in tumor infiltrating and stromal lympho-
cytes were evaluated separately. The number of PD-1-positive cells were counted on a total
field of 2.2 mm2 using the ImageJ program (version 1.46r). For categorical analyses, the infil-
tration of positive PD-1 cells per 2.2mm2 was scored as no infiltration (0 to 8 cells), low infil-
tration (9 to 39 cells) and high infiltration (more than 39 cells). PD-1 expression in tumor
infiltrating and stromal lymphocytes were evaluable in 36/38 samples.
PD-L1 expression was evaluated using the scoring system as described by Kim et al. [23] to
evaluate the intensity and the area of staining, separately in tumor and stromal areas at the
tumor front. Staining intensity was graded semi-quantitatively as: 0 for negative staining, 1 for
weakly positive staining, 2 for moderately positive staining and 3 for strongly positive staining.
Area of staining was scored as 0 for 0–10% stained cells, 1 for 11–33% stained cells, 2 for 34–
66% stained cells and 3 for 67–100% stained cells. A combined PD-L1 score was defined as the
sum of the intensity score and the area of staining score, with a minimum score of zero and a
maximum combined score of six. For categorical analyses, total scores were divided into three
groups: 0 for no expression, 1 to 2 for low expression, and 3 to 6 for high expression. PD-L1
expression in tumoral and stromal areas were evaluable in 38/38 and 37/38 samples,
respectively.
Statistical analysis
Statistical analyses for categorical and non-categorical variables were performed using Chi-
Square/ Fisher’s Exact and Mann-Whitney U/ Student’s t tests as described in the manuscript
or figure legends. All tests were two-sided. p-values <0.05 were considered statistically
VEGFA amplification and the tumor microenvironment
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significant. All analyses were performed using Graphpad Prism 6.0 (Graphpad Software, Inc.,
La Jolla, CA) or R x64 Version 3.2.1 (http://www.R-project.org).
Results
VEGFA copy number assessment and sample selection
To identify cases of CRC with VEGFA gene amplification, we screened a TMA consisting of
150 CRCs by FISH for VEGFA gene amplification and/or chromosome 6 (Chr6) polysomy. Of
the 124 evaluable samples, we identified 11 samples (9%) with VEGFA amplification and none
that displayed Chr6 polysomy. The remaining 113 samples (91%) were VEGFA copy number
neutral. In addition, we retrieved the whole sections from eight cases previously found to har-
bor VEGFA amplification (n = 2) or Chr6 polysomy (n = 6) [35]. In total, we selected the 19
CRCs with VEGFA amplification (n = 13) or Chr6 polysomy (n = 6) and the same number of
VEGFA copy number neutral CRCs (n = 19) as control (Fig 1 and S1 Table). Most the included
CRCs were of intermediate tumor grade (i.e. grade 2, n = 29) and the remaining were of high
grade (i.e. grade 3, n = 9, S1 Table). The VEGFA status stratified on the histologic grade
revealed that in the intermediate tumor grade CRCs VEGFA was amplified, polysomic or dip-
loid in 38% (11/29), 14% (4/29) and 48% (14/29) respectively. In the CRCs of high tumor
grade VEGFA was amplified, polysomic or diploid in 22% (2/9), 22% (2/9) and 56% (5/29)
respectively. Further analysis revealed that there were no differences in sex, T/N/M stage,
tumor grade, lymphatic and venous invasion between the VEGFA amplified/polysomic and
the control group (p>0.05, Chi-square tests).
VEGFA amplification/polysomy is associated with reduced M1 and M2 macrophages.
To determine the distribution of macrophages in CRCs, we performed immunohistochemical
analysis using CD68 as a marker for both M1 and M2 macrophages and CD163 as a marker
for M2 macrophages [6]. In the 38 CRCs included in our cohort, both CD68-positive cells and
CD163-positive cells were almost exclusively located in the tissue surrounding the tumors,
especially along invasive tumor front (Fig 2). Semi-quantitative evaluation of CD68 and
CD163 expression at the tumor front revealed that 16 (42%), 13 (34%) and 9 (24%) CRCs had
low, moderate and high infiltration of CD68-positive cells, respectively, and 33 (87%), 3 (8%)
and 2 (5%) CRCs had low, moderate and high infiltration of CD-163-positive cells, respectively
(S2 Table).
Statistical analysis between the number of CD68- and CD163-positive cells with and with-
out VEGFA copy number amplification/ polysomy revealed reduced CD68-positive cells in
CRCs with VEGFA gene amplification or Chr6 polysomy compared to those that were VEGFA
copy number neutral (p = 0.0015, Mann–Whitney U test; Fig 3A). When we categorized the
number of CD68-positive cells into low, moderate and high infiltration, a predominantly low
infiltration (p = 0.0139, Chi-square test, S2 Table) was found in CRCs harboring VEGFA gene
amplification or Chr6 polysomy. Similarly, we observed fewer CD163-positive cells in
CRCs with VEGFA gene amplification/ Chr6 polysomy than VEGFA copy number neutral
CRCs (p = 0.02, Mann–Whitney U test; Fig 3B). However, there was no statistical difference
we categorized the number of CD163-positive cells into low, moderate and high infiltration
(p = 0.218, Chi-square test, S2 Table). We further observed that both CD68 and CD163
infiltration were increased in high-grade tumors (grade 3) compared to intermediate-grade
tumors (grade 2, p = 0.001 and p<0.0001, respectively, Mann–Whitney U tests; Fig 3C and
3D and p = 0.002 and p<0.0001, respectively, Chi-square test, S2 Table). The increased CD-
163 positive cells are M2 macrophages. The fraction of M1 macrophages was on the con-
trary reduced in high-grade cases.
VEGFA amplification and the tumor microenvironment
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Taken together, these results suggest that CRCs with VEGFA gene amplification or Chr6
polysomy are associated with reduced M1/M2 (CD68-positive) and M2 (CD163-positive)
macrophage infiltration, whilst high-grade CRCs are associated with increased M2 and
reduced M1 macrophage infiltration.
VEGFA amplification/polysomy is associated with reduced PD-1-positive tumor lym-
phocytes and PD-L1 stromal expression. Next we investigated the association of VEGFA
gene copy number status with the presence of PD-1-positive tumor infiltrating and stromal
lymphocytes and PD-L1 tumoral and stromal expression at the tumor front. In this cohort, we
observed no PD-1-expressing tumor infiltrating lymphocytes and PD-L1 tumoral expression
in 50% and 66% of the CRCs analyzed. By contrast, PD-1 positive lymphocytes were present
and PD-L1 was expressed in the stroma in 89% and 92% of cases respectively (S2 Table).
Similar to the reduction in M1 and M2 macrophages, CRCs with VEGFA amplification or
Chr6 polysomy were preferentially associated with the absence of or the reduction in PD-
1-positive tumor infiltrating lymphocytes than in VEGFA copy number neutral CRCs
(p = 0.0188, Chi-square test; Fig 4A), but were not different from VEGFA copy number neutral
CRCs in terms of the number of PD-1-positive stromal lymphocytes (p = 0.3868, Chi-square test;
Fig 4B). We further observed no difference in PD-L1-tumoral expression between CRCs with
VEGFA amplification or Chr6 polysomy and VEGFA copy number neutral CRCs (p = 0.407,
Chi-square test; Fig 4C). However, we observed that CRCs with VEGFA amplification or Chr6
Fig 1. VEGFA copy number status in colorectal cancers measured by fluorescent in situ hybridization.
Representative micrographs of (A) diploid, (B) polysomic and (C) amplified VEGFA using fluorescent in situ hybridization
(FISH). FISH analysis was performed using two-color probes for VEGFA (red) and internal control (green). Scale bar 20 μm.
https://doi.org/10.1371/journal.pone.0175563.g001
VEGFA amplification and the tumor microenvironment
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polysomy had lower PD-L1 expression in the stroma than in VEGFA copy number neutral CRCs
(p = 0.0079, Chi-square test; Fig 4D). Neither PD-1-positive tumor infiltrating nor stromal lym-
phocytes was associated with tumor grade (p = 0.4355 and p = 0.839, respectively, Chi-square
tests; S2 Table). However, increased tumoral but not stromal PD-L1 expression was associated
with high-grade (grade 3) compared to intermediate-grade tumors (grade 2, p = 0.0173 and
p = 0.4743, respectively, Chi-square test; S2 Table).
Taken together, these results suggest that CRCs with VEGFA gene amplification or Chr6
polysomy are associated with reduced PD-1-positive tumor infiltrating lymphocytes and
PD-L1 stromal expression.
Discussion
To understand the immune microenvironment of CRCs with VEGFA gene copy number
amplification or Chr6 polysomy, we performed a hypothesis-generating immunohistochemi-
cal analysis and found an association between VEGFA gene copy number amplification or
Chr6 polysomy and reduced number of M1 and M2 macrophages, reduced PD-1-expressing
lymphocyte infiltration, as well as reduced stromal expression of PD-L1 at the tumor front.
We further observed a higher number of M2 macrophages and increased PD-L1 tumoral
expression in high-grade tumor compared with intermediate-grade CRCs.
In accordance with Forssell et al. [18], we observed that most CD68+ and/or CD163+ mac-
rophages were found in the stroma along the tumor front. This suggests that macrophages are
attracted to or recruited to the invasive front. In high-grade tumors these were mostly CD163
+, M2 macrophages. These results are in keeping with similar data recently obtained in other
neoplastic entities as gastric and lung carcinoma [48,49]. In addition, M2 macrophage polari-
zation has been reported to be significantly associated with advanced histopathologic stage
and the presence of metastasis, probably mediated by Caspase recruitment domain-containing
Fig 2. Distribution of macrophages in colorectal cancers, using CD68 and CD163 markers. Representative
micrographs of (A, C) CD68+ cells and (B, D) CD163+ cells (A, B) at the invasive tumor front (T) and (C, D) in the
surrounding tumor tissue (S). Magnification 40X. Scale bar 20 μm.
https://doi.org/10.1371/journal.pone.0175563.g002
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protein 9 (CARD9) through activation of the nuclear factor-kappa B signaling pathway [50].
Moreover, we further found that VEGFA gene copy number amplification or Chr6 polysomy,
a feature that characterizes a subset of aggressive CRCs, was associated with reduced TAMs.
These results are in agreement with the previous report linking high CD68+ macrophage infil-
tration at the tumor front of CRC to improved survival of patients [18]. By contrast, this subset
of aggressive CRCs is also associated with lower levels of PD-1-positive tumor infiltrating lym-
phocytes but high levels of PD-1-positive tumor infiltrating lymphocytes have been robustly
associated with poor survival in many cancers [23,26,30–32]. Unfortunately due to the limited
number of cases, we were unable to perform survival analysis for this cohort.
VEGFA has previously been associated with immunosuppression in tumors [41,42]. In
addition to being produced by a substantial proportion of tumors and being over-expressed
when amplified [38–40], VEGFA is also secreted by various cell types, including macro-
phages and lymphocytes, in the tumor microenvironment. Our observations led to the
hypothesis that VEGFA amplification may suppress the attraction of macrophages and lym-
phocytes towards the tumor front. We speculate that pre-angiogenic tumor tissues, which
do not harbor the VEGFA gene copy number amplification and therefore express low levels
of VEGFA, send signals to the bone marrow and/or the blood circulation that lead to the
recruitment of the macrophages [51]. Once in the proximity of the tumor, the macrophages
release metalloproteinases, such as MMP-9. MMP-9 cleaves the components in the
Fig 3. Number of macrophages in colorectal cancers, using CD68 and CD163 markers. Boxplots depict the number of
(A, C) CD68+ and (B, D) CD163+ cells (A, B) in CRCs with and without VEGFA amplification/polysomy and (C, D) in CRCs
of intermediate and high grade.
https://doi.org/10.1371/journal.pone.0175563.g003
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extracellular matrix, releasing VEGFA from its sequestered state and inducing angiogenesis
around the tumor, as seen in hyperplastic islet of Langerhans [51]. By contrast, we speculate
that the recruitment process of TAMs may not occur in tumors harboring VEGFA gene
amplification, as the additional VEGFA secreted by surrounding cells may no longer pro-
vide a growth advantage. The observation that VEGFA amplified/polysomic CRCs had both
reduced numbers of CD68-positive and/or CD163+ macrophages and lower PD-L1 stromal
expression may further support our hypothesis, since PD-L1 has been reported to be over-
expressed in macrophages [51].
Although our cohort in the study was small and the markers used for the identification of
macrophages may be imperfect, we found a consistent pattern of macrophages at the tumor
front using two markers, in agreement with a previous study [18]. It would be of interest to
investigate whether the adverse prognosis associated with the extent of macrophage infiltration
in CRC and other cancer types [19–21] overlaps with the aggressive nature of CRCs associated
with VEGFA amplification.
Conclusions
In summary, we have identified an association between VEGFA gene amplification in CRC
and reduced macrophages, PD-1-positive infiltrating lymphocytes and PD-L1 stromal expres-
sion at the tumor front. Further studies are needed to clarify the role of VEGFA on the
Fig 4. PD-1-positive tumor infiltrating and stromal lymphocytes and PD-L1 tumoral and stromal expression in colorectal
cancers. Barplots depict the number of samples with high, low and negative expression of (A, B) PD-1 and (C, D) PD-L1 in (A, C)
tumoral and (B, D) stromal areas of CRCs.
https://doi.org/10.1371/journal.pone.0175563.g004
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interaction of CRCs and their tumor microenvironment and to provide mechanistic insight
into these observations.
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